CytoDyn Inc. (CYDY)
| Previous close | 1.2765 |
| Open | 1.2400 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.1500 - 1.2800 |
| 52-week range | 1.0800 - 7.4000 |
| Volume | 1,984,751 |
| Avg. volume | 2,415,596 |
| Market cap | 783.318M |
| Beta (5Y monthly) | -1.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2550 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
CytoDyn Announces Preliminary Results from 2021 Annual Meeting
VANCOUVER, Wash., November 24, 2021--CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced the preliminary vote results from the 2021 Annual Meeting of Stockholders (the "Annual Meeting"), which was held today.
- Business Wire
Leronlimab (350 mg) Weekly Use for 14 Weeks in Open Label Arm of NASH Trial Produces Fibrosis Reduction as High as 93 msec Amongst First 15 Patients with Average Reduction of 24 msec
VANCOUVER, Wash., November 24, 2021--CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today reported data from its trial treating NASH (nonalcoholic steatohepatitis) open label with leronlimab.
- Business Wire
CytoDyn Research Paper on Leronlimab Published in Frontiers in Immunology Journal
VANCOUVER, Wash., November 19, 2021--CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that its research paper entitled "CCR5 receptor occupancy analysis reveals increased peripheral blood CCR5+CD4+ T cells following treatment with the anti-CCR5 antibody Leronlimab" has been accepted by Frontiers in Immunology, a leading journal in its field
